Hanan M Qasem, Ramez M Odat, Sakhr Alshwayyat, Jehad A Yasin, Osama M Younis, Ayham Mohammad Hussein, Hritvik Jain, Mohammad Abdelraheem, Bishr Quwaider, Dang Nguyen
{"title":"头颈部鳞状细胞癌中吲哚胺 2,3-二氧化酶 (IDO) 表达的临床病理和预后意义：系统综述和元分析。","authors":"Hanan M Qasem, Ramez M Odat, Sakhr Alshwayyat, Jehad A Yasin, Osama M Younis, Ayham Mohammad Hussein, Hritvik Jain, Mohammad Abdelraheem, Bishr Quwaider, Dang Nguyen","doi":"10.1016/j.jormas.2024.102130","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising antitumor target and predictive biomarker in a variety of cancers. Hence, we performed this meta-analysis to evaluate the clinicopathological and prognostic significance of IDO1 in head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>We searched PubMed, Embase, Web of Science and Scopus databases from inception to May 2024, to identify studies measuring the clinicopathological and prognostic significance of IDO1 in HNSCC. The role of IDO1 in HNSCC was evaluated by pooled hazard ratios (HR), odd ratios (OR) and 95% confidence intervals (CI). The meta-analysis was performed using the meta package in R. Omics analyses on IDO1 were also performed.</p><p><strong>Results: </strong>Ten studies (1,119 participants) were included in the review. The analysis showed an insignificant relationship between IDO1 expression and poor overall survival, and progression free survival as indicated by the pooled HR (HR: 1.65, 95% CI: 0.68-4.02), (HR: 1.73, 95% CI: 0.63-4.77), respectively. Additionally, elevated expression of IDO1 was significantly associated with tumor T stage (OR: 1.44, 95% CI: 1.06-1.94). However, it was insignificantly correlated with positive lymph node metastasis (N status) (OR: 1.11; 95% CI: 0.82-1.50) and tumor-node-metastasis (TNM) stage (OR: 1.14; 95% CI: 0.79-1.64).</p><p><strong>Conclusion: </strong>While higher IDO1 expression is associated with the risk of advanced tumor stage in HNSCC, its impact on overall and progression-free survival remains inconclusive. Further research is needed to elucidate its prognostic significance and therapeutic potential.</p>","PeriodicalId":56038,"journal":{"name":"Journal of Stomatology Oral and Maxillofacial Surgery","volume":" ","pages":"102130"},"PeriodicalIF":2.2000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinicopathological and prognostic significance of indoleamine 2,3-dioxygenase (IDO) expression in head and neck squamous cell carcinoma: A systematic review and meta-analysis.\",\"authors\":\"Hanan M Qasem, Ramez M Odat, Sakhr Alshwayyat, Jehad A Yasin, Osama M Younis, Ayham Mohammad Hussein, Hritvik Jain, Mohammad Abdelraheem, Bishr Quwaider, Dang Nguyen\",\"doi\":\"10.1016/j.jormas.2024.102130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising antitumor target and predictive biomarker in a variety of cancers. Hence, we performed this meta-analysis to evaluate the clinicopathological and prognostic significance of IDO1 in head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>We searched PubMed, Embase, Web of Science and Scopus databases from inception to May 2024, to identify studies measuring the clinicopathological and prognostic significance of IDO1 in HNSCC. The role of IDO1 in HNSCC was evaluated by pooled hazard ratios (HR), odd ratios (OR) and 95% confidence intervals (CI). The meta-analysis was performed using the meta package in R. Omics analyses on IDO1 were also performed.</p><p><strong>Results: </strong>Ten studies (1,119 participants) were included in the review. The analysis showed an insignificant relationship between IDO1 expression and poor overall survival, and progression free survival as indicated by the pooled HR (HR: 1.65, 95% CI: 0.68-4.02), (HR: 1.73, 95% CI: 0.63-4.77), respectively. Additionally, elevated expression of IDO1 was significantly associated with tumor T stage (OR: 1.44, 95% CI: 1.06-1.94). However, it was insignificantly correlated with positive lymph node metastasis (N status) (OR: 1.11; 95% CI: 0.82-1.50) and tumor-node-metastasis (TNM) stage (OR: 1.14; 95% CI: 0.79-1.64).</p><p><strong>Conclusion: </strong>While higher IDO1 expression is associated with the risk of advanced tumor stage in HNSCC, its impact on overall and progression-free survival remains inconclusive. Further research is needed to elucidate its prognostic significance and therapeutic potential.</p>\",\"PeriodicalId\":56038,\"journal\":{\"name\":\"Journal of Stomatology Oral and Maxillofacial Surgery\",\"volume\":\" \",\"pages\":\"102130\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Stomatology Oral and Maxillofacial Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jormas.2024.102130\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Dentistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stomatology Oral and Maxillofacial Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jormas.2024.102130","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Dentistry","Score":null,"Total":0}
引用次数: 0
摘要
研究目的吲哚胺-2,3-二氧合酶-1（IDO1）是一种很有前景的抗肿瘤靶点，也是多种癌症的预测性生物标志物。因此，我们进行了这项荟萃分析，以评估 IDO1 在头颈部鳞状细胞癌（HNSCC）中的临床病理和预后意义：方法：我们检索了PubMed、Embase、Web of Science和Scopus数据库中从开始到2024年5月有关IDO1在HNSCC中的临床病理学和预后意义的研究。IDO1在HNSCC中的作用通过汇总的危险比（HR）、奇数比（OR）和95%置信区间（CI）进行评估。荟萃分析使用 R 中的 meta 软件包进行，还对 IDO1 进行了 Omics 分析：10项研究（1,119名参与者）被纳入综述。分析结果显示，IDO1表达与总生存期和无进展生存期之间的关系并不显著，汇总HR分别为（HR：1.65，95% CI：0.68-4.02）和（HR：1.73，95% CI：0.63-4.77）。此外，IDO1表达的升高与肿瘤T分期显著相关（OR：1.44，95% CI：1.06-1.94）。然而，它与淋巴结转移（N 状态）阳性（OR：1.11；95% CI：0.82-1.50）和肿瘤-结节-转移（TNM）分期（OR：1.14；95% CI：0.79-1.64）的相关性不明显：结论：虽然IDO1的高表达与HNSCC的肿瘤晚期风险有关，但其对总生存期和无进展生存期的影响仍不确定。结论：虽然 IDO1 表达较高与 HNSCC 肿瘤晚期风险有关，但其对总生存期和无进展生存期的影响仍无定论，需要进一步研究以阐明其预后意义和治疗潜力。
Clinicopathological and prognostic significance of indoleamine 2,3-dioxygenase (IDO) expression in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Objective: Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising antitumor target and predictive biomarker in a variety of cancers. Hence, we performed this meta-analysis to evaluate the clinicopathological and prognostic significance of IDO1 in head and neck squamous cell carcinoma (HNSCC).
Methods: We searched PubMed, Embase, Web of Science and Scopus databases from inception to May 2024, to identify studies measuring the clinicopathological and prognostic significance of IDO1 in HNSCC. The role of IDO1 in HNSCC was evaluated by pooled hazard ratios (HR), odd ratios (OR) and 95% confidence intervals (CI). The meta-analysis was performed using the meta package in R. Omics analyses on IDO1 were also performed.
Results: Ten studies (1,119 participants) were included in the review. The analysis showed an insignificant relationship between IDO1 expression and poor overall survival, and progression free survival as indicated by the pooled HR (HR: 1.65, 95% CI: 0.68-4.02), (HR: 1.73, 95% CI: 0.63-4.77), respectively. Additionally, elevated expression of IDO1 was significantly associated with tumor T stage (OR: 1.44, 95% CI: 1.06-1.94). However, it was insignificantly correlated with positive lymph node metastasis (N status) (OR: 1.11; 95% CI: 0.82-1.50) and tumor-node-metastasis (TNM) stage (OR: 1.14; 95% CI: 0.79-1.64).
Conclusion: While higher IDO1 expression is associated with the risk of advanced tumor stage in HNSCC, its impact on overall and progression-free survival remains inconclusive. Further research is needed to elucidate its prognostic significance and therapeutic potential.
期刊介绍：
J Stomatol Oral Maxillofac Surg publishes research papers and techniques - (guest) editorials, original articles, reviews, technical notes, case reports, images, letters to the editor, guidelines - dedicated to enhancing surgical expertise in all fields relevant to oral and maxillofacial surgery: from plastic and reconstructive surgery of the face, oral surgery and medicine, … to dentofacial and maxillofacial orthopedics.
Original articles include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses.
All manuscripts submitted to the journal are subjected to peer review by international experts, and must:
Be written in excellent English, clear and easy to understand, precise and concise;
Bring new, interesting, valid information - and improve clinical care or guide future research;
Be solely the work of the author(s) stated;
Not have been previously published elsewhere and not be under consideration by another journal;
Be in accordance with the journal''s Guide for Authors'' instructions: manuscripts that fail to comply with these rules may be returned to the authors without being reviewed.
Under no circumstances does the journal guarantee publication before the editorial board makes its final decision.
The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey Platforms.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
